eDiagnosis(SZ:002932) Sou Hu Cai Jing·2025-05-26 09:11Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company was 16.37% [1] Market Position - The company's current stock price is 18.75 yuan, with a decline of 1.16% [1] - The rolling price-to-earnings (PE) ratio is 112.35, significantly higher than the industry average of 48.92 and the industry median of 35.68, placing the company at the 108th position in the industry ranking [1][2] - The total market capitalization of the company is 4.36 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1]